Open an account

Icecure Medical

ICCM · NASDAQ

$1.01+$0.01 (+1.00%)TodayMarket closed ·
Prev close $1.00

About ICCM

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. The firm operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

Employees
68
Headquarters
CAESAREA, Haifa
Listed
Feb 2, 2011
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
icecure-medical.com

ICCM key statistics

Market cap
3.46M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
193.97K
Volume
42.35K
Open price
$1.02
High today
$1.07
Low today
$1.01
52 Week high
$24.90
52 Week low
$0.9601

Icecure Medical (ICCM) at a glance

As of Oct 23, 2026, Icecure Medical (ICCM) shares are priced at $1.01, giving the company a market cap of 3.46M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.01 and $1.07. The current price is 0.0% above the day's low and 5.6% below its high.

Volume so far is 42.35K shares, below the average of 193.97K shares a day.

Over the past year Icecure Medical has ranged from $0.9601 to $24.90, and now sits 0% of the way up that range.

Icecure Medical met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$3.11 per share against an estimate of -$1.53.

The average analyst price target is $23.12, 2189.1% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $23.12
Low
$10.10
Now
$1.01
High
$31.50

ICCM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 18.0% on average.

  1. Q3 FY24: reported -$2.40 per share against an estimate of -$2.30
  2. Q4 FY24: reported -$2.40 per share against an estimate of -$2.30
  3. Q1 FY25: reported -$1.80 per share against an estimate of -$2.45
  4. Q2 FY25: reported -$1.80 per share against an estimate of -$1.99
  5. Q3 FY25: reported -$1.80 per share against an estimate of -$1.53
  6. Q4 FY25: reported -$2.10 per share against an estimate of -$1.38
  7. Q1 FY26: reported -$1.80 per share against an estimate of -$1.43
  8. Q2 FY26: reported -$3.11 per share against an estimate of -$1.53

ICCM news

  • Press releasePRNewswire

    IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

  • Press releasePRNewswire

    IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

  • Press releasePRNewswire

    IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

  • Press releasePRNewswire

    IceCure Medical Receives Regulatory Approval to Market ProSense® in China

  • Press releasePRNewswire

    IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

  • Press releasePRNewswire

    West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

  • Press releasePRNewswire

    IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

  • Press releasePRNewswire

    IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

Similar companies

Companies in the same industry as Icecure Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.